Thrombocytopenia after autologous stem cell transplantation

Aim. Characteristics of thrombocytopenia and finding ways of predicting platelet transfusions at autologous hematopoietic stem cell transplantation in patients with hematologic and autoimmune diseases. Methods. Thrombocytopenia period after autologous hematopoietic stem cell transplantation in patients with autoimmune (group I, n=87) and hematological (group II, n=82) diseases was evaluated. Results. It was revealed that in patients with hematological oncologic diseases platelet count before the transplantation and on the first day after it is connected with the length of thrombocytopenia and the number of transfused platelets units. In patients with autoimmune diseases, low platelet count on the first day after transplantation might be used as a predictor for the transfusion risk. Day of thrombocytopenia onset is predictive of its duration and the need for blood components. In patients with hematological oncologic diseases, severe thrombocytopenia at day 14 before the transfusion is associated with further transfusion of 3 or more units of platelets. Platelet count at the first day after the transfusion is related to the number of platelet units transfused and thrombocytopenia duration. Onset of thrombocytopenia with platelet count lower than 20 and 10×109/L is predictive of its duration and the need for blood components. In patients with hematological oncologic diseases, early onset of thrombocytopenia is associated with further transfusion of larger doses of platelets. Conclusion. The revealed differences may be used as the criteria for predicting platelet transfusions in patients after autologous hematopoietic stem cell transplantation.

transfusion, platelets, transplantation, stem cells, multiple sclerosis, polyneuropathy, ankylosing spondylitis, multiple myeloma, non-Hodgkin’s lymphoma, Hodgkin’s disease